Catch up on the latest headlines in this week’s episode of Eyewire News: The Podcast. Aldeyra resubmits its NDA for reproxalap for DED, Clearside Biomedical reports positive phase 2b results from its investigational wet AMD drug, and Bausch + Lomb launches a user-friendly digital marketplace: https://bit.ly/4f1GoWm
Eyewire+
Book and Periodical Publishing
Wayne, PA 10,722 followers
Eyewire+ is devoted to keeping readers updated with the latest information in the ophthalmic and eye care fields.
About us
Eyewire+ keeps readers updated with the latest in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, videos, and other news sources. EyewireTV is the only weekly news broadcast devoted entirely to the ophthalmic industry.
- Website
-
https://eyewire.news/
External link for Eyewire+
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- Wayne, PA
- Specialties
- eye care, optometry, opthalmology, ophthalmics, doctors, medicine, med students, media, publishing, and news
Updates
-
Nanoscope Therapeutics Inc.has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP): https://bit.ly/3BIT71O
-
Aldeyra resubmits its application for its dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches of a new digital e-commerce marketplace. Continue watching out latest episode of EyewireTV here: https://bit.ly/4813vxI
-
Clearside Biomedical, Inc. announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints: https://bit.ly/4dE1VmS
Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMD - Eyewire+
eyewire.news
-
Marinomed Biotech AG has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis: https://bit.ly/3NhCRXV
Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitis - Eyewire+
eyewire.news
-
New week, new updates! Welcome to another edition of Eyewire+ Weekly Digest! Get up to speed with the most recent news in ophthalmology and optometry, along with new podcasts, EyewireTV content, and in-depth subspecialty expertise. Start exploring now! 👁️
Trending Stories on Eyewire+
Eyewire+ on LinkedIn
-
In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia: https://bit.ly/4dACfaK
Cure Blindness Project Unveils Global Expansion Plan on World Sight Day - Eyewire+
eyewire.news
-
In a new study, researchers led by Sue Menko, PhD, of Thomas Jefferson University, have revealed how immune cells play a critical role in resolving inflammation on the surface of the eye’s lens: https://bit.ly/3Bpxkf9
-
Check out this week's Eyewire News: The Podcast covering Novaliq’s water-free ciclosporin eye drop approval in Europe, the first FDA-approved new ophthalmic steroid in 15 years, and the launch of a slit lamp-mounted rebound tonometer in the US and Europe: https://bit.ly/4eQJXhI
-
Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for its investigational topical drug, reproxalap, which is intended to treat the signs and symptoms of dry eye disease: https://bit.ly/3Y6FF0j
Aldeyra Resubmits NDA for Topical Ocular Reproxalap for Dry Eye Disease - Eyewire+
eyewire.news